Taysha Gene Therapies is trading 5.11% higher at $3.81 on October 19, with broader biotech strength providing supportive context; no company-specific catalyst is confirmed.

  • Biotech shares are up 2.09% during the regular session.
  • October 19 coverage revisited previously reported Rett syndrome trial results, not fresh data.